4551 - 4575 of 8808 Results
Title
Year
-
OPENTitle: Cholinergic system changes in Parkinson's disease: emerging therapeutic approachesJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 4Start Page: 381End Page: 392Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00377-xBest OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/8985079Citation Count: 220
-
RESTRICTEDTitle: Movement disorders research in 2021: cracking the paradigmJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 10End Page: 11Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00413-0Citation Count: 18
-
RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 145
-
RESTRICTEDTitle: Revisiting levodopa for advanced Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1063End Page: 1065Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5Citation Count: 1
-
RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 13
-
OPENTitle: Brain health: The hidden casualty of a humanitarian crisisJournal Name: The Lancet Regional Health - EuropePublisher: Elsevier BVVol: 15Issue #:Start Page: 100374End Page: 100374Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.lanepe.2022.100374Best OA location URL: https://doi.org/10.1016/j.lanepe.2022.100374Citation Count: 5
-
OPENTitle: Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based studyJournal Name: The Lancet Regional Health - AmericasPublisher: Elsevier BVVol: 7Issue #:Start Page: 100136End Page: 100136Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-nd, cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.lana.2021.100136Best OA location URL: https://doi.org/10.1016/j.lana.2021.100136Citation Count: 38
-
OPENTitle: Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing ageJournal Name: eBioMedicinePublisher: Elsevier BVVol: 82Issue #:Start Page: 104179End Page: 104179Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104179Best OA location URL: http://www.thelancet.com/article/S2352396422003607/pdfCitation Count: 33
-
OPENTitle: Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJournal Name: eBioMedicinePublisher: Elsevier BVVol: 80Issue #:Start Page: 104021End Page: 104021Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104021Best OA location URL: http://www.thelancet.com/article/S2352396422002055/pdfCitation Count: 61
-
OPENTitle: The role of primary and secondary delays in the effective resonance frequency of acoustically interacting microbubblesJournal Name: Ultrasonics SonochemistryPublisher: Elsevier BVVol: 86Issue #:Start Page: 106033End Page: 106033Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ultsonch.2022.106033Best OA location URL: https://doi.org/10.1016/j.ultsonch.2022.106033Citation Count: 16
-
OPENTitle: Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiologyJournal Name: eBioMedicinePublisher: Elsevier BVVol: 85Issue #:Start Page: 104290End Page: 104290Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104290Best OA location URL: http://www.thelancet.com/article/S2352396422004728/pdfCitation Count: 22
-
OPENTitle: Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose AdjustmentJournal Name: European Medical JournalPublisher: European Medical GroupVol:Issue #:Start Page: 20End Page: 27Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.33590/emj/10022165Best OA location URL: https://www.emjreviews.com/wp-content/uploads/2022/12/Tailoring-Motor-Fluctuation-Treatment-Beyond-Levodopa-Dose-Adjustment-1.pdfCitation Count: 0
-
OPENTitle: Botulinum Toxin in the Treatment of Cervical Dystonia: Evidence-Based ReviewJournal Name: DystoniaPublisher: Frontiers Media SAVol: 1Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/dyst.2022.10655Best OA location URL: https://www.frontierspartnerships.org/articles/10.3389/dyst.2022.10655/pdfCitation Count: 6
-
OPENTitle: Tele-Yoga for the Management of Cervical Dystonia: A Safety and Feasibility TrialJournal Name: DystoniaPublisher: Frontiers Media SAVol: 1Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/dyst.2021.10015Best OA location URL: https://www.frontierspartnerships.org/articles/10.3389/dyst.2021.10015/pdfCitation Count: 0
-
OPENTitle: The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged HumansJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.902191Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2022.902191/pdfCitation Count: 7
-
OPENTitle: Editorial: Non-neuronal cell heterogeneity in the nervous system during health and diseaseJournal Name: Frontiers in Cellular NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.3389/fncel.2022.1047296Best OA location URL: https://www.frontiersin.org/articles/10.3389/fncel.2022.1047296/pdfCitation Count: 1
-
OPENTitle: Editorial: Digital Innovation and Data-Driven Research in Neurodegenerative DiseasesJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.961847Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.961847/pdfCitation Count: 0
-
OPENTitle: Editorial: Cannabinoids in neuroinflammation, neurodegeneration and pain: Focus on non-neuronal cellsJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.1114775Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.1114775/pdfCitation Count: 1
-
OPENTitle: Editorial: LRRK2—Fifteen Years From Cloning to the ClinicJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.880914Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.880914/pdfCitation Count: 1
-
RESTRICTEDTitle: An Overview of the Active Clinical Trials for Parkinson’s Disease PsychosisJournal Name: Neurodegenerative Disease ManagementPublisher: Informa UK LimitedVol: 12Issue #: 4Start Page: 165End Page: 170Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.2217/nmt-2022-0020Citation Count: 0
-
RESTRICTEDTitle: Die Folgen der Schulgeldfreiheit – Wissenschaft nachgefragtJournal Name: physiopraxisPublisher: Georg Thieme Verlag KGVol: 20Issue #: 05Start Page: 12End Page: 13Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1055/a-1815-6034Citation Count: 1
-
OPENTitle: Opicapone in Uk Clinical Practice: effectiveness, Safety and Cost Analysis in Patients With Parkinson’s DiseaseJournal Name: Neurodegenerative Disease ManagementPublisher: Informa UK LimitedVol: 12Issue #: 2Start Page: 77End Page: 91Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.2217/nmt-2021-0057Best OA location URL: https://eprints.ncl.ac.uk/281877Citation Count: 6
-
RESTRICTEDTitle: Schwungvolles Gehen – Musikalisches Feedback in der ParkinsontherapieJournal Name: physiopraxisPublisher: Georg Thieme Verlag KGVol: 20Issue #: 05Start Page: 34End Page: 37Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1055/a-1788-9184Citation Count: 0
- Targeted Metabolomic Analysis in Alzheimer’s Disease Plasma and Brain Tissue in Non-Hispanic Whites2022OPENTitle: Targeted Metabolomic Analysis in Alzheimer’s Disease Plasma and Brain Tissue in Non-Hispanic WhitesJournal Name: Journal of Alzheimer's DiseasePublisher: SAGE PublicationsVol: 86Issue #: 4Start Page: 1875End Page: 1895Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jad-215448Best OA location URL: https://content.iospress.com:443/download/journal-of-alzheimers-disease/jad215448?id=journal-of-alzheimers-disease%2Fjad215448Citation Count: 39
-
RESTRICTEDTitle: Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer’s Disease and Primary Tauopathy Postmortem BrainsJournal Name: Journal of Alzheimer's DiseasePublisher: SAGE PublicationsVol: 88Issue #: 1Start Page: 207End Page: 228Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.3233/jad-220125Citation Count: 13